LÁSZLÓ CZIRÁKI, M.D.; MÁRIA Oó, M.D.
To the editor: A recent paper in this journal (1) stresses the advantages of intermittent cyclophosphamide, methotrexate, and fluorouracil plus prednisone therapy in metastatic breast cancer. We have had experience with the simpler combination of chlorambucil plus prednisolone (2). The triple combination of cyclophosphamide, methotrexate, and prednisolone, and methyltestosterone alone were also used, however, with no better effect.
Fifty-two consecutive patients (in a 10-year period) received chlorambucil-prednisone in 139 cycles. A cycle consists of chlorambucil 20 mg/day plus prednisolone 30 to 40 mg/day for 2 weeks. The dose of the cytostatic is then reduced to 10 mg/day, whereas the prednisone
CZIRÁKI L, Oó M. Combination Therapy in Metastatic Breast Cancer. Ann Intern Med. ;86:364–365. doi: 10.7326/0003-4819-86-3-364_3
Download citation file:
Published: Ann Intern Med. 1977;86(3):364-365.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use